# reload+after+2024-01-23 08:46:38.243203
address1§225 Franklin Street
address2§26th Floor
city§Boston
state§MA
zip§02110
country§United States
phone§857 246 8998
website§https://www.pieris.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§127
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Stephen S. Yoder J.D.', 'age': 47, 'title': 'CEO, President & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 774715, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Bures', 'age': 49, 'title': 'Senior VP & CFO', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 499378, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Maria  Kelman', 'title': 'Executive Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frank  Vollmering', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Shane  Olwill Ph.D.', 'age': 47, 'title': 'Senior VP & Chief Development Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Prompong  Chaikul', 'age': 36, 'title': 'Chief Supply Chain Officer', 'yearBorn': 1987, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Florian  Witte Ph.D.', 'title': 'VP and Head of Alliance Management & Early Project Leadership', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.526
priceToSalesTrailing12Months§0.3677958
currency§USD
dateShortInterest§1702598400
forwardEps§-0.2
exchange§NCM
quoteType§EQUITY
shortName§Pieris Pharmaceuticals, Inc.
longName§Pieris Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1420209000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8fe43177-b19a-3ae9-9f2a-563a55a71915
gmtOffSetMilliseconds§-18000000
recommendationMean§2.5
recommendationKey§buy
quickRatio§1.589
grossMargins§-0.07116
ebitdaMargins§-0.40552
trailingPegRatio§None
